Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of ABT-089 in mild-to-moderate Alzheimer's disease
NCT00809510Phase 2Terminated
- Sponsor
- Abbott Laboratories
- Start
- Jan 2009
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pozanicline in Alzheimer's disease (AD), sponsored by Abbott Laboratories. Started Jan 2009; status: terminated.
02
Drugs
pozanicline
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00809510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00809510.